Cambridge-based Closed Loop Medicine, a techbio company developing combination prescription drug and software therapy products that deliver personalised dose optimisation, has appointed Paul Johnson as an independent non-executive director.

Johnson has experience of the digital healthcare industry, having co-founded Lemonaid Health, a direct-to-consumer telehealth app in the US, and led the company as chief executive through to its acquisition by consumer genetics and research company, 23andMe, for $400 million in 2021. Johnson then became vice-president and general manager, and later chief operating officer, of the wider 23andMe consumer business, which includes Lemonaid Health. Prior to moving to the US, Johnson was head of online at McKesson UK, where he was responsible for the online profit and loss and all digital activity for the group’s brands, including Lloyds Pharmacy. In 2010, as UK managing director, he launched the Zooplus business in the UK, a European online pet shop. Johnson is an advisor to several technology companies and venture funds; he is a chief executive coach and an active angel investor.

Johnson said: “Closed Loop Medicine’s approach to delivering personalised and integrated healthcare aligns with my commitment to building digital product experiences that treat patients as individuals, rather than an average of a population set. Throughout my career, I’ve championed digital solutions to provide accessible healthcare for all. With its proprietary dose optimisation platform, the company is going a step further to improve outcomes at the individual level. It is clear I am joining Closed Loop Medicine at a very transformative stage in its development, and I am very much looking forward to supporting the company in bringing forward the promise of precision care, as it realises the potential of its product pipeline.”

Dr Hakim Yadi co-founder and chief executive of Closed Loop Medicine, said: “As we stand on the brink of realising our vast prospects within the industry, Paul’s strategic insights and proven track record will be instrumental to steering the company to continued growth and success. His notable achievements and deep expertise in navigating the evolving telemedicine and digital health landscape, particularly through his work at Lemonaid Health and 23andMe, will undoubtedly play a focal role in bolstering the company’s strategic growth and commercialization of our disruptive platforms.”